» Articles » PMID: 20622510

Cell Culture Processes for Monoclonal Antibody Production

Overview
Journal MAbs
Date 2010 Jul 13
PMID 20622510
Citations 168
Authors
Affiliations
Soon will be listed here.
Abstract

Animal cell culture technology has advanced significantly over the last few decades and is now generally considered a reliable, robust and relatively mature technology. A range of biotherapeutics are currently synthesized using cell culture methods in large scale manufacturing facilities that produce products for both commercial use and clinical studies. The robust implementation of this technology requires optimization of a number of variables, including 1) cell lines capable of synthesizing the required molecules at high productivities that ensure low operating cost; 2) culture media and bioreactor culture conditions that achieve both the requisite productivity and meet product quality specifications; 3) appropriate on-line and off-line sensors capable of providing information that enhances process knowledge; and 4) good understanding of culture performance at different scales to ensure smooth scale-up. Successful implementation also requires appropriate strategies for process development, scale-up and process characterization and validation that enable robust operation that is compliant with current regulations. This review provides an overview of the state-of-the art technology in key aspects of cell culture, e.g., engineering of highly productive cell lines and optimization of cell culture process conditions. We also summarize the current thinking on appropriate process development strategies and process advances that might affect process development.

Citing Articles

A Versatile Fabrication Route for Screening of Block Copolymer Membranes in Bioprocessing.

Meng K, Alvarez-Fernandez A, Guldin S, Bracewell D ACS Omega. 2025; 10(8):8630-8639.

PMID: 40060785 PMC: 11886646. DOI: 10.1021/acsomega.4c11269.


Monoclonal Antibodies in Metastatic Gastro-Esophageal Cancers: An Overview of the Latest Therapeutic Advances.

Kalofonou F, Kalofonou M, Dimitrakopoulos F, Kalofonos H Int J Mol Sci. 2025; 26(3).

PMID: 39940858 PMC: 11816984. DOI: 10.3390/ijms26031090.


Optimization of Culture Conditions to Improve Follicle-Stimulating Hormone Production by CHO-DG44 Cells in Serum-Free Medium.

Ghobadian H, Roshanzamir K, Kouhi Abdolabadi M, Ostadi H, Zati Keikha R, Dolatkhah Baghan M Iran Biomed J. 2025; 28(5 & 6):282-96.

PMID: 39901854 PMC: 11829159. DOI: 10.61186/ibj.4160.


Genetically modified chickens as bioreactors for protein-based drugs.

Meng S, Miao A, Wu S, Du X, Gao F Front Genome Ed. 2025; 6():1522837.

PMID: 39845893 PMC: 11753250. DOI: 10.3389/fgeed.2024.1522837.


Transcriptomics as a predictor of biopharmaceutically favourable glycan profiles.

West B, Kotidis P, Istrate A, Perna D, Finka G, Wood A Front Cell Dev Biol. 2025; 12:1504381.

PMID: 39741638 PMC: 11686447. DOI: 10.3389/fcell.2024.1504381.


References
1.
Chirino A, Mire-Sluis A . Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004; 22(11):1383-91. DOI: 10.1038/nbt1030. View

2.
Wurm F . Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004; 22(11):1393-8. DOI: 10.1038/nbt1026. View

3.
Goerke A, Swartz J . Development of cell-free protein synthesis platforms for disulfide bonded proteins. Biotechnol Bioeng. 2007; 99(2):351-67. DOI: 10.1002/bit.21567. View

4.
Davies J, Jiang L, Pan L, LaBarre M, Anderson D, Reff M . Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng. 2001; 74(4):288-94. View

5.
Kimura R, Miller W . Glycosylation of CHO-derived recombinant tPA produced under elevated pCO2. Biotechnol Prog. 1997; 13(3):311-7. DOI: 10.1021/bp9700162. View